The role of complement and activated microglia in the pathogenesis of Alzheimer's disease

Neurobiology of Aging

Volumn 17, Issue 5, 1996, Pages 673-680

  Eikelenboom, P ^a,b   Veerhuis, R ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b PCA Valeriuskliniek ^*  (Netherlands)

Author keywords

Alzheimer's disease; Complement; Inflammation; Microglia; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; COMPLEMENT ACTIVATION; HUMAN; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0030250852     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-4580(96)00108-X     Document Type: Article

References (99)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501; 1988.
2. 2. Akiyama, H.; Kawamata, T.; Dedhar, S.; McGeer, P. L. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J. Neuroimmunol. 32:19-28; 1991.
3. 3. Aulak, K. S.; Donaldson, V. H.; Coutinho, M.; Davis, A. E., III. Cl-inhibitor: Structure/function and biologic role. Behring Inst. Mitt. 93: 204-214; 1993.
4. 4. Bauer, J.; Strauss, S.; Schreiter-Gasser, U.; Ganter, U,; Schlegel, P.; Witt, I.; Yolk, B.; Berger, M. Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285:111-114; 1991.
5. 5. Bauer, J.; Ganter, U.; Strauss, S.; Stadtmuller, G.; Frommberger, U.; Bauer, H.; Volk, B.; Berger, M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143:650-657; 1992.
6. 6. Bobak, D. A.; Frank, M. M.; Tenner, A. J. C1q acts synergistically with phorbol dibutyrate to activate CR1-mediated phagocytotis by human mononuclear phagocytes. Eur. J. Immunol. 18:2001-2007; 1988.
7. 7. Brun, A.; Englund, E. Regional pattern of degeneration in Alzheimer's disease: Neuronal loss and histopathological grading. Histopathology 5:549-564; 1981.
8. 8. Colton, C. A.; Gilbert, D. L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223:284-288; 1987.
9. 9. Delaere, P.; Duyckaerts, C.; He, Y.; Piette, F.; Hauw, J. J. Subtypes and differential laminar distributions of β/A4 deposits in Alzheimer's disease: Relationship with intellectual status of 26 cases. Acta Neuropathol. (Berl.) 81:328-335; 1991.
10. 10. Dickson, D. W.; Lee, S. C.; Mattiace, L. A.; Yen, S. C.; Brosnan, C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83; 1993.
11. 11. Eikelenboom, P.; Stam, F. C. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. (Berl.) 57:239-242; 1982.
12. 12. Eikelenboom, P.; Vink-Starreveld, M. L.; Jansen, W.; Pronk, J. C. C3 and haptoglobin polymorphism in dementia of the Alzheimer type. Acta Psychiatr. Scand. 69:140-142; 1984.
13. 13. Eikelenboom, P.; Goetz, G.; Pronk, J. C.; Hauptmann, G. Complement C4 phenotypes in dementia of the Alzheimer type. Hum. Hered. 38: 48-51; 1988.
14. 14. Eikelenboom, P.; Fraser, H.; Rozemuller, J. M.; Stam, F. C. The blood-brain barrier in cerebral amyloidogenesis in Alzheimer's disease and scrapie. In: Pouplard-Barthelaix, A.; Emile, J.; Christensen, Y., eds. Immunology and Alzheimer's disease. Berlin: Springer Verlag; 1988:30-41; 1988.
15. 15. Eikelenboom, P.; Hack, C. E.; Rozemuller, J. M.; Stam, F. C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B Cell Pathol. 56:259-262; 1989.
16. 16. Eikelenboom, P.; Rozemuller, J. M.; Fraser, H.; Berkenbosch, F.; Kamphorst, W.; Stam, F. C. Neuroimmunological mechanisms in cerebral amyloid deposition in Alzheimer's disease. In: Ishii, T.; Allsop, D.; Selkoe, D. J., eds. Frontiers in Alzheimer's disease. New York: Elsevier Science Publishers; 1991:259-271.
17. 17. Eikelenboom, P.; Rozemuller, J. M.; Kraal, G., Stam, F. C.; McBride, P. A.; Bruce, M. E.; Fraser, H. Cerebral amyloid deposits in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch. B Cell Pathol. 60:329-336; 1991.
18. 1-antichymotrypsin in cerebral β/A4 deposits in Alzheimer's disease. Res. Immunol. 143:617-620; 1992.
19. 19. Eikelenboom, P.; Zhan, S.-S.; Van Gool, W. A.; Allsop, D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol. Sci. 15:447-150; 1994.
20. 20. Eikelenboom, P.; Zhan, S.-S.; Kamphorst, W.; van der Valk, P.; Rozemuller, J. M. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid deposits in Alzheimer's disease. Virchows Arch, 424:421-427; 1994.
21. 21. Emsley, J.; White, H. E.; O'Hara, B. P.; Oliva, G.; Srinivasan, N.; Tickle, I. J.; BlundelL T. L.; Pepys, M. B.; Wood, S. P. Structure of pentameric human serum amyloid P component. Nature 367:338-345; 1994.
22. 1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA 92:2313-2317; 1995.
23. 1-Antichymotrypsin binding to Alzheimer Aβ peptides in sequence specific and induces fibril disaggregation in vitro. J. Neurochem. 61:298-305; 1993.
24. 24. Frohman, E. M.; Frohman, T. C.; Gupta, S.; de Fougerolles, A.; van de Noort, S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J. Neurol. Sci. 106:105-111; 1991.
25. 25. Gasque, P.; Ischenko, A.; Legoedec, J.; Mauger, C.; Schouft, M.-T.; Fontaine, M. Expression of the complement classical pathway by human glioma in culture. J. Biol. Chem. 268:25068-25074; 1993.
26. 26. Gewurz, H.; Ying, S.-C; Jiang, H.; Lint, T. F. Nonimmune activation of the classical complement pathway. Behring Inst. Mitt. 93:138-147; 1993.
27. 27. Ghiso, J.; Matsubara, E.; Koudinov, A.; Choi-Miura, N, H.; Tomita, M.; Wisniewski, T.; Frangione, B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293:27-30; 1993.
28. 28. Gordon, G. L.; Sadlon, T. A.; Wesselingh, S. L.; Russell, S. M.; Johnstone, R. W.; Purcell, D. F. J. Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. J. Neuroimmunol. 36:199-208; 1992.
29. 29. Griffin, W. S. T.; Stanley, L. C.; Ling, C.; White, L.; MacLeod, V.; Perrot, L. C.; White, C. L.; Araoz, C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down. Proc, Natl Acad. Sci. USA 86:7611-7615; 1989.
30. 30. Griffin, W. S. T.; Sheng, J. G.; Roberts, G. W.; Mrak, R. E. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54: 276-281; 1995.
31. 31. Haga, S.; Ikeda, K.; Sato, M,; Ishii, T. Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 601:88-94; 1993.
32. 32. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12:383-388; 1991.
33. 33. Hyman, B. T.; Marzloff, K.; Arriagada, P. V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52:594-600; 1993.
34. 34. Ishii, T.; Haga, S. Immuno-electron microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. (Berl.) 63:296-300; 1984.
35. 35. Itagaki, S.; Akiyama, H.; Saito, H.; McGeer, P. L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645:78-84; 1994.
36. 36. Jiang, H.; Burdick, D.; Glabe, C. G.; Cotman, C. W.; Tenner, A. J. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:5050-5059; 1994.
37. 37. Johnson, S. A.; Lampert-Etchells, M.; Pasinetti, G. M.; Rozovsky, I.; Finch, C. E. Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging 13:641-648; 1992.
38. 38. Kalaria, R. N. The immunopathology of Alzheimer's disease and some related disorders. Brain Pathol. 3:333-347; 1993.
39. 39. Kalaria, R. N.; Kroon, S. N. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer's disease. Biochem. Biophys. Res. Commun. 186:461-466; 1992.
40. 40. Korotzer, A. R.; Watt, J.; Cribbs, D,; Tenner, A. J.; Burdick, D.; Glabe, C.; Cotman, C. W. Cultured rat microglia express C1q and receptor for C1q: Implications for amyloid effects on microglia. Exp. Neurol. 134:214-221; 1995.
41. 41. Lacy, M.; Jones, J.; Whittemore, S. R.; Haviland, D. L.; Wetsel, R. A.; Barnum, S. R. Expression of receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J. Neuroimmunol. 6:71-78; 1995.
42. 42. Lampert-Etchells, M.; Pasinetti, G. M.; Finch, C. E.; Johnson, S.A. Regional localization of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease. Neurodegeneration 2:111-121; 1993.
43. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94; 1994.
44. 44. Maat-Schieman, M. L. C.; Rozemuller, A. J.; Van Duinen, S. G.; Haan, J.; Eikelenboom, P., Roos, R. A. C. Microglia in diffuse plaques in hereditary cerebral haemorrhage with amyloidosis (Dutch). An immunohistochemical study. J. Neuropathol. Exp. Neurol. 53:483-491; 1994.
45. 45. Mann, D. M. A.; Jones, D.; Prinja, D.; Purkiss, M. S. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol. 80:318-327; 1990.
46. 46. May, P. C.; Finch, C. E. Sulfated glycoprotein 2: New relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15:391-396; 1992.
47. 47. McGeer, P. L.; Itagaki, S.; Tago. H.; McGeer E. G. Reactive microglia in patients with senile dementia of Alzheimer's type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:195-200; 1987.
48. 48. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Immune response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527; 1989.
49. 49. McGeer, P. L.; Walker, D. G.; Akiyama, H.; Kawamata, T.; Guan, A. L.; Parker, C. J.; Okada, N.; McGeer, E. G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544:315-319; 1991.
50. 50. McGeer, P. L.; McGeer, E. G. Complement proteins and complement inhibitors in Alzheimer's disease. Res. Immunol. 143:621-624; 1992.
51. 51. McGeer, P. L.; Kawamata, T.; Walker, D. G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:337-341; 1992.
52. 52. Mehne, P.; Grünwald, P.; Gerner Beuerle, E. Ein serogenetische Beitrag zur ätiopathogenese der Alzheimerischen Erkrankung. Akt. Geront. 6:259-264; 1976.
53. 53. Morgan, E. L.; Sanderson, S.; Scholtz, W.; Noonan, D. J.; Weigle, W. O.; Hugh, T. E. Identification and characterization of the effector region within human C5a responsible for stimulation of Il-6 synthesis. J. Immunol. 148:3937-3942; 1992.
54. 54. Nerl, C.; Mayeux, R.; O'Neill, G. J. HLA-linked complement markers in Alzheimer's and Parkinson's disease C4 variant (C4B2)-A possible marker for senile dementia of the Alzheimer type. Neurology 24:310-314; 1984.
55. 55. Ogomori, K.; Kitamoto, T.; Tateishi, J.; Sato, Y; Suetsaga, M.; Abe, M. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am. J. Pathol. 134:234-251; 1989.
56. 56. Panegyres, P. K.; Dawkins, R. L. Complement allotypes in familial and sporadic Alzheimer's disease. J. Neurol. 238:325-326; 1991.
57. 57. Pasinetti, G. M.; Johnson, S. A.; Rozovsky, I.; Lampert-Etchells, M.; Morgan, D. G.; Gordon, M. N.; Willoughby, D.; Finch, C. E. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp. Neurol. 118:117-125; 1992.
58. 1-antichymotrypsin mRNA. Am. J. Pathol. 135:827-834; 1989.
59. 59. Pike, C. J.; Burdick, D.; Walecewicz, A. J.; Glabe, G.G.; Cotman, C. W. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J. Neurosci. 13:16776-1687; 1993.
60. 60. Pouplard, A.; Emile, J. New immunological findings in senile dementia. Interdiscipl. Topics Geront. 19:62-71; 1985.
61. 61. Pouplard-Barthelaix A. Immunological markers and neuropathological lesions in Alzheimer's disease. In: Pouplard-Barthelaix, A.; Emile, J.; Christen, Y., eds. Immunology and Alzheimer's disease. Berlin: Springer Verlag; 1988:7-16.
62. 62. Preissner, K. T. Structure and biological role of vitronectin. Annu. Rev. Cell. Biol. 7:275-310; 1991.
63. 63. Rogers, J.; Luber-Narod, J.; Styren, S.D.; Civin, W. H. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol. Aging 9:339-349; 1988.
64. 64. Rogers, J.; Schultz, J.; Brachova, L.; Lue, L.-F.; Webster, S.; Bradt, B.; Cooper, N. R.; Moss, D.E. Complement activation and β-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143: 624-630; 1992.
65. 65. Rogers, J.; Cooper, N, R.; Webster, S.; Schultz, J.; McGeer, P. L.; Styren, S. D.; Civin, W. H.; Brachova, L.; Bradt, B.; Ward, P.; Lieberburg, I. Complement activation by β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 89:10016-10020; 1992.
66. 66. Rozemuller, J. M.; Eikelenboom, P.; Kamphorst, W.; Stam, F. C. Lack of evidence for blood-brain barrier dysfunction in Alzheimer's disease: An immunohistochemical study. Neurobiol. Aging 9:383-391; 1988.
67. 67. Rozemuller, J. M.; Eikelenboom, P.; Stam, F. C.; Beyreuther, K.; Masters, C. L. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extra cellulair amyloid deposition. J. Neuropathol. Exp. Neurol. 48:674-691; 1989.
68. 68. Rozemuller, J. M.; Eikelenboom, P.; Pals, S.; Stam, F. C. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:282-292; 1989.
69. 69. Rozemuller, J. M.; Stam, F. C.; Eikelenboom, P. Acute phase proteins are present in amorphous plaques in the cerebral but not cerebellar cortex in patients with Alzheimer's disease. Neurosci, Lett. 119:75-78; 1990.
70. 70. Rozemuller, J. M.; Abbink, J.; Stam, F. C.; Hack, C. E.; Eikelenboom, P. Distribution pattern and functional state of alpha-1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. Acta Neuropathol. (Berl.) 82:200-207; 1991.
71. 71. Rozemuller, J. M.; Bots, G. T. A. M.; Roos, R. A. C.; Eikelenboom, P. Acute phase proteins but not activated microglial cells are present in parenchymal β/A4 deposits in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neurosci. Lett. 140:137-140; 1992.
72. 72. Rozemuller, J. M.; Valk, P. van der; Eikelenboom, P. Activated microglia and cerebral amyloid deposits in Alzheimer's disease. Res. Immunol. 43:646-649, 1992.
73. 73. Selkoe, D. J. The molecular pathology of Alzheimer's disease. Neuron 6:487-498; 1991.
74. 74. Selkoe, D. J. Amyloid β-protein precursor: New clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4:708-716; 1994.
75. 75. Smyth, M. D.; Cribbs, D. H.; Tenner, A. J.; Shankle, W. R.; Dick, M.; Kesslak, J. P.; Cotman, C. W. Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state, Neurobiol. Aging 15:609-614; 1994.
76. 76. Snow, A. D.; Sekiguchi, R. T.; Nochlin, D.; Kalaria, R. N.; Kimata, K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am. J. Pathol. 144: 337-347; 1994.
77. 77. Snow, A. D.; Sekiguchi, R.; Nochlin, D.; Fraser, P.; Kimata, K.; Mizutani, A.; Arai, M.; Schreier, W. A.; Morgan, D. G. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar β-Amylod in rat brain. Neuron 12:219-234; 1994.
78. 78. Snyder, S.W.; Wang, G. T.; Barrett, L.; Ladror, U. S.; Casuto, D.; Lee, C. M.; Krafft, G. A.; Holzman, R. B.; Holzman, T. F. Complement C1q does not bind to monomeric β-amyloid. Exp. Neurol. 128: 136-142; 1994.
79. 79. Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; Pericak-Vance, M.; Enghild, J.; Salvesen, G. S.; Roses, A. D. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:1977-1981; 1993.
80. 80. Tagliavini, F.; Giaccone, G.; Frangione, B.; Bugiani, O. Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci. Lett. 93:191-196; 1988.
81. 81. Tenner, A. J. Functional aspects of the C1q receptors. Behring Inst. Mitt. 93:241-253; 1993.
82. 82. Väkevä, A.; Laurila, P.; Meri, S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab. Invest. 67:608-616; 1992.
83. 83. Vandenabeele, P.; Fiers, W. Is amyloidogenesis during Alzheimer's disease due to an Il-1/Il-6-mediated "acute phase response" in the brain? Immunol. Today 12:217-219; 1991.
84. 84. Van Muiswinkel, F. L.; Veerhuis, R.; Eikelenboom, P. Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorbol-myristate-acetate induced respiratory burst activity. J. Neurochem. 66:2468-2476; 1996.
85. 85. Veerhuis, R.; Van Es, L. A.; Daha, M. R. Effects of soluble aggregates of Ig on the binding, uptake and degradation of the C1q subcomponent of complement by adherent guinea pig peritoneal macrophages. Eur. J. Immunol. 23:881-887; 1985.
86. 86. Veerhuis, R.; Zhan, S.-S.; Eikelenboom, P. Role of inflammation and complement activation in Alzheimer's disease. In: Zatta, P.; Nicolini M., eds, Non-neuronal cells in Alzheimer's disease. Singapore: World Scientific Publishers; 1995:171-193.
87. 87. Veerhuis, R.; Van der Valk, P.; Janssen, I.; Zhan, S.-S.; Van Nostrand, W. E.; Eikelenboom, P. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch. 426:603-610; 1995.
88. 88. Veerhuis, R.; Janssen, I.; Hack, C. E.; Eikelenboom, P. Early complement components in Alzheimer's disease brains. Acta Neuropathol. 91:53-60; 1996.
89. 89. Veerhuis, R.; Ghebrehiwet, B.; Hogan, T. H.; Pasinetti, G. M. Immunolocalization of receptors for the globular and collagen region of the complement component CIq in Alzheimer disease brain. Soc. Neurosci. Abstr. 21:147-148; 1995.
90. 90. Verbeek, M. M.; Otte-Höller, I.; Westphal, J. R.; Wesseling, P.; Ruiter, D. J.; Waal, R. M. W. de. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144:104-116; 1994.
91. 91. Walker, D. G.; McGeer, P. L. Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Mol. Brain. Res. 14:109-116; 1992.
92. 92. Walker, D. G.; Yasuhara, O.; Patston, P. A.; McGeer, E. G.; McGeer, P. L. Complement C1 Inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 675:75-82; 1995.
93. 93. Webster, S.; O'Barr, S.; Rogers, J. Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1q. J. Neurosci. Res. 39:448-456; 1994.
94. 94. Wright, S. D.; Craigmyle, L. S.; Silverstein, S. C. Fibronectin and serum amyloid P component stimulate C3b-and C3bi-mediated phagocytosis in cultured human monocytes. J. Exp. Med. 158:1338-1343; 1983.
95. 95. Yamaguchi, H.; Hirai, S.; Morimatsa, M.; Shoji, M.; Ihary, Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by β-protein immunostaining. Acta Neuropathol. (Berl.) 76:541-549; 1988.
96. 96. Yang, C.; Jones, J. L.; Barnum, S. R. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J. Neuroimmunol. 47:123-132; 1993.
97. 97. Zhan, S. S.; Veerhuis, R.; Janssen, I.; Kamphorst, W.; Eikelenboom, P. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease. Neurodegeneration 3: 111-117; 1994.
98. 98. Zhan, S. S.; Veerhuis, R.; Kamphorst, W.; Eikelenboom, P. Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the nondemented elderly. Neurodegeneration 43:291-297; 1995.
99. 99. Ziccardi, R. J.; Cooper, N. R. Active disassembly of the first complement component, C1, by C1 inactivator. J. Immunol. 123:788-792; 1979.